Caroline Palomeque
Stock Analyst at Maxim Group
(2.57)
# 2,184
Out of 4,905 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $2.52 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $35.20 | +67.61% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $147.49 | +4.41% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $56.45 | +2.75% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $169.90 | -2.30% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $14.00 | +178.57% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $8.16 | +647.55% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $10.98 | +264.30% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.52
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $35.20
Upside: +67.61%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $147.49
Upside: +4.41%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $56.45
Upside: +2.75%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $169.90
Upside: -2.30%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $14.00
Upside: +178.57%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $8.16
Upside: +647.55%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $10.98
Upside: +264.30%